What makes Biotech’s Future? AI, Equity, and the Innovation Edge in Massachusetts

It was energizing to hear from life sciences leaders at the Boston Business Journal’s event, “Biotech’s Future: Innovation, AI and Our Competitive Edge.” The conversation shed light on where the industry is headed—and what it will take to stay ahead.

The key themes? Artificial intelligence, equity, talent —and the unshakable spirit that has defined Massachusetts’ leadership in biotech.

Equity and Inclusion Must Be Part of the Innovation Equation

While our state remains at the forefront of the life sciences industry, the sector faces mounting challenges with biotech layoffs, reduced public funding, and growing competition from emerging hubs in states like Utah and North Carolina. But the strengths are still here: unparalleled academic institutions, a deep talent pool, public-private collaboration, and an unmatched density of innovation hubs.

Kirk Taylor, president and CEO of the Massachusetts Life Sciences Center (MLSC), discussed how the MLSC has launched a health equity grant program, reflecting the Healy administration’s commitment to diversity in biotech.

The message: talent exists everywhere—not just in Boston or Cambridge—and the industry must do more to recognize and support it. From workforce development to expanding access to capital, inclusion will be a key driver of innovation going forward. There is a growing need for talent at the intersection of multiple disciplines, and we must continue to encourage and nurture the next generation of scientists.  

AI is Already Reshaping Biotech

From drug discovery to clinical trial design, artificial intelligence is more than a buzzword—it’s accelerating outcomes that would have been impossible just months ago. Companies like Lila Sciences, an AI-first biotech company, and Seaport Therapeutics, are proving what’s possible when cutting-edge science meets machine learning.

Integrating AI into clinical workflows comes with challenges. It’s not just about building models—it’s about ensuring real-world validation, structuring clean data pipelines, and implementing AI at a pace the industry can realistically manage.

Challenges in Real Estate and Capital Markets

With venture capital still largely on the sidelines and lab space vacancy rising, Massachusetts’ real estate market is adapting. Companies are rethinking their physical footprints, particularly as AI and digital platforms reduce the need for traditional lab setups. It is changing and reshaping the way companies use space, affecting the lab space ecosystem.

A Call for Optimism—and Action

Despite the headwinds, the tone of the event remained hopeful. As one speaker reminded the audience, five years ago to the day, we were in the depths of a global pandemic and lockdown. Today, thanks to the same scientific ingenuity and collective will, the biotech community is poised to tackle the next wave of challenges. Panelists noted good science will prevail, and companies should continue to focus on addressing unmet needs and getting to the next milestone.

There’s no question Massachusetts has the chops to stay at the top—if we continue to invest in talent, support innovation, and adapt to new realities. Panelists are optimistic about what AI can do to accelerate and enhance science. Despite job growth being largely stagnant, Massachusetts still outpaces much of the country in terms of job postings and employment growth.

We’ll continue to monitor the evolving life sciences landscape in Massachusetts and beyond to provide valuable insights for our clients and opportunities for growth.  

‍